DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Bile acids, 1346–1347
Bile acid sequestrant agents, 1336–1337
Bile-acid sequestrants, 898–899
adverse effects of, 899
chemistry of, 898–899
drug interactions with, 899
and lipoprotein levels, 899
mechanism of action of, 899
structures of, 898f
therapeutic uses of, 899
Bile acid synthesis, 127
Bile salt export pump (BSEP), 93, 107
Bile salt malabsorption, primary, 102t
Bile salts, ABC transporters and, 105t
Biliary excretion, 26
Biliary tract
muscarinic antagonists and, 229
opioids and, 498
Bilirubin monoglucoronide, 105t
Bimatoprost, 952
for glaucoma, 1787
nor-Binaltorphimine, actions and
selectivities of, 485t
Bioavailability
absorption vs., 19
of common drugs, 1809t–1890t
definition of, 19
disposition and, 28
extent of, 33–34
factors influencing, 20
first-pass effect and, 19–20
hepatic disease and, 1802
in parenteral administration, 20
as pharmacodynamic parameter,
1802
rate of, 33–34
Biocompatible polymers, 23
Bioequivalence, 23
Biological agents
classes, 1824
in dermatology, 1824–1827, 1825t
for inflammatory bowel disease,
1359–1360
for psoriasis, 1824
mechanism of action of, 1826f
Biological induction therapy,
1006–1007
Biological License Application (BLA),
79
Biological response modifier(s), in
cancer treatment, 1745–1750
Biological response modifiers
for inflammatory bowel disease,
1352t
for neoplastic disease, 1668t–1670t
Biological toxins, 575
Biotransformation, in liver, 27
Biperiden, 234
Bipolar (manic-depressive) disorder
lithium for, 447
prophylactic treatment of, 448
Birth defects, oral anticoagulantinduced,
864
Bishydroxycoumarin, 860
Bismuth compounds, 1337
Bisoctrizole, 1827
Bisoprolol, 312f, 327–328
as antihypertensive agent, 774t
Bisphosphonates, 1294–1296
absorption of, 1296
adverse effects of, 1296
excretion of, 1296
for osteoporosis, 1299
Bitolterol, 292f, 293
Bivalirudin, 859–860
therapeutic uses of, in myocardial
ischemia, 771
BLA. See Biological License
Application (BLA)
“Black box,” 9
Bladder, urinary
ABC transporters in, 106t
acetylcholine and, 221–222
atony, anticholinesterase agents for,
250
in autonomic nervous system, 179t
bethanechol and, 224
choline esters and, 223t
muscarinic antagonists and, 231
opioids and, 497
Bladder cancer, drugs for, 1668t–1670t
BLENOXANE (bleomycin), 1823
Bleomycin(s), 1668t–1670t
for cancer, 1716–1718
intralesional
adverse effects and side effects of,
1823
for squamous cell carcinoma,
1823
for warts, 1823
mechanism of action of, 1820t
systemic, for Kaposi sarcoma, 1823
Blepharitis
fungal, 1784t
yeast, 1784t
Blepharoconjunctivitis, bacterial,
treatment of, 1781t
Blinking, 1773
Blistering diseases, autoimmune, 1816
mycophenolate mofetil for, 1823
Blodd-cerebrospinal fluid barrier,
intrathecal injection and, 22
Blood-brain barrier (BBB), 365–366
ABC transporters and, 104
distribution of drugs and, 25
intrathecal injection and, 22
transporters and, 91–93, 116
vectorial transport in, 96f
Blood-cerebrospinal fluid barrier
intrathecal injection and, 22
transporters and, 116
Blood circulation, muscarinic
antagonists and, 228
Blood dyscrasias, androgens for, 1204
Blood pressure
angiotensin II and, 727f, 730
epinephrine and, 282–283
kinins and, 931
normal, in adults, 773t
pharmacological lowering of, effects
on RAS, 746t, 747
regulation, role of kidneys and fluids
and electrolytes, 698f
Blood vessels
alpha adrenergic receptors in, 203t
in autonomic nervous system, 178t
BMS-354825 (dasatinib), 1732
Body temperature
ethanol and, 637
muscarinic antagonists and,
229–230
opioids and, 498
Bolus injection, 22
Bone
disorders of, 1286–1290
distribution in, 24–25
eicosanoids and, 951
infections of, quinolones for, 1473
mass, 1285
parathyroid hormone and, 1279
physiology, 1285–1286
remodeling, 1285–1286
skeletal organization and, 1285
Bone marrow, alkylating agents and,
1681
Bone mineral, mobilization of, vitamin
D and, 1283
Bone mineral density (BMD)
bone physiology and, 1285
postmenopausal, estrogens and,
1838
Bortezomib, 1742–1743
absorption, 1743
chemistry, 1742
elimination, 1743
2005
INDEX